About: Enarodustat

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH). The drug was approved in September 2020 in Japan for anemia associated with CKD and is currently in clinical development in the United States and South Korea. The drug is being developed by Japan Tobacco and JW Pharmaceutical.

Property	Value
dbo:abstract	Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH). The drug was approved in September 2020 in Japan for anemia associated with CKD and is currently in clinical development in the United States and South Korea. The drug is being developed by Japan Tobacco and JW Pharmaceutical. (en)
dbo:alternativeName	Enaroy (en)
dbo:casNumber	1262132-81-9
dbo:chEMBL	4297619
dbo:drugbank	14985
dbo:fdaUniiCode	JSK7TUA223
dbo:kegg	D11523
dbo:pubchem	50899324
dbo:thumbnail	wiki-commons:Special:FilePath/Enarodustat.svg?width=300
dbo:wikiPageID	67950097 (xsd:integer)
dbo:wikiPageLength	4093 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1029776124 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Drugs_acting_on_the_blood_and_blood_forming_organs dbc:Carboxylic_acids dbc:Triazolopyridines dbr:Anemia dbr:HIF_prolyl-hydroxylase_inhibitor dbr:Drug_development dbr:Chronic_kidney_disease dbr:Japan_Tobacco dbc:Amides dbc:Secondary_amino_acids
dbp:c	17 (xsd:integer)
dbp:casNumber	1262132 (xsd:integer)
dbp:chembl	4297619 (xsd:integer)
dbp:chemspiderid	64835234 (xsd:integer)
dbp:drugName	Enarodustat (en)
dbp:drugbank	14985 (xsd:integer)
dbp:h	16 (xsd:integer)
dbp:iupacName	2 (xsd:integer)
dbp:kegg	D11523 (en)
dbp:legalStatus	Rx-only (en)
dbp:n	4 (xsd:integer)
dbp:o	4 (xsd:integer)
dbp:pubchem	50899324 (xsd:integer)
dbp:smiles	C1=CC=CCCC2=CCCCNCCO (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	FJYRBJKWDXVHHO-UHFFFAOYSA-N (en)
dbp:synonyms	JTZ-951 (en)
dbp:tradename	Enaroy (en)
dbp:unii	JSK7TUA223 (en)
dbp:wikiPageUsesTemplate	dbt:Infobox_drug dbt:Reflist dbt:Blood-drug-stub
dcterms:subject	dbc:Drugs_acting_on_the_blood_and_blood_forming_organs dbc:Carboxylic_acids dbc:Triazolopyridines dbc:Amides dbc:Secondary_amino_acids
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH). The drug was approved in September 2020 in Japan for anemia associated with CKD and is currently in clinical development in the United States and South Korea. The drug is being developed by Japan Tobacco and JW Pharmaceutical. (en)
rdfs:label	Enarodustat (en)
owl:sameAs	wikidata:Enarodustat https://global.dbpedia.org/id/FondP
prov:wasDerivedFrom	wikipedia-en:Enarodustat?oldid=1029776124&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Enarodustat.svg
foaf:isPrimaryTopicOf	wikipedia-en:Enarodustat
foaf:name	Enarodustat (en)
is dbo:wikiPageRedirects of	dbr:Enaroy dbr:JTZ-951
is dbo:wikiPageWikiLink of	dbr:HIF_prolyl-hydroxylase_inhibitor dbr:Enaroy dbr:Triazolopyridine dbr:JTZ-951
is foaf:primaryTopic of	wikipedia-en:Enarodustat